Today: 19 May 2026
South32 share price slides nearly 5% as metals meltdown hits miners — what to watch before results
2 February 2026
1 min read

South32 share price slides nearly 5% as metals meltdown hits miners — what to watch before results

Sydney, Feb 2, 2026, 16:46 AEDT — After-hours

  • South32 dropped roughly 4.5% to A$4.41 amid falling metals prices and weaker risk appetite
  • A steep drop in gold and silver weighed on the broader market, pulling mining stocks down with it
  • Investors are turning their attention to the RBA on Tuesday and South32’s half-year results set for Feb. 12

Shares of South32 Ltd dropped roughly 4.5% on Monday, closing at A$4.41 after dipping to a low of A$4.29 during the session, according to data. The stock had ended at A$4.62 previously.

The drop followed a turbulent day for commodities-linked stocks, triggered by frantic selling in precious metals that spilled over into wider markets. Traders blamed margin calls—demands for additional cash to maintain leveraged futures positions—as the selloff accelerated on its own momentum.

“This seems less about one trigger and more like a typical de-leveraging and liquidity squeeze,” Marc Velan, head of investments at Lucerne Asset Management in Singapore, told Reuters. He warned that “further downside is possible,” noting markets will react sharply if forced selling persists. Reuters

The Australian and New Zealand dollars dipped after Kevin Warsh was named the frontrunner to lead the U.S. Federal Reserve, Reuters reported. The U.S. dollar gained ground, putting pressure on commodities priced in dollars. In Australia, all eyes are on Tuesday’s Reserve Bank decision, where a 0.25-point rate hike is widely expected, according to Reuters.

Gold dropped roughly 4.7% today, with silver plunging over 9%, according to Trading Economics data. Copper also slipped about 3.5%. These swings in base metals hit diversified miners hard, since spot prices tend to shape short-term sentiment, even if earnings don’t keep pace.

The wider market mood weighed on stocks, with Australia’s ASX 200 slipping roughly 1%. Miners took a hit amid falling commodity prices — BHP dropped 2.3%, while Rio Tinto lost 1.0%, according to ABC.

South32 operates across a range of metals, including alumina and aluminium, copper, silver-lead-zinc, and manganese, according to a Reuters company profile. This diversity helps cushion the impact of downturns in any one metal but also means the stock can take a hit if multiple commodities slide simultaneously.

Focus turns sharply to company-specific triggers. South32 has set Feb. 12 for its half-year results ending Dec. 31, 2025, and will also declare its interim dividend on that date, the company confirmed in its calendar update.

But there’s a snag for those reading too deeply into Monday’s drop. Should gold and silver find a floor — or forced selling ease — miners could bounce back quickly, reversing much of the decline in short order. If volatility sticks around, though, investors may continue trimming positions ahead of earnings, keeping shares unsettled through mid-February.

Traders now turn to offshore markets to see if precious metals can hold their ground, while Tuesday’s RBA decision looms as a potential catalyst for Australian assets. South32’s spotlight moment comes on Feb. 12, when it reports half-year results and announces its dividend.

Stock Market Today

  • LeMaitre Q1 Performance Trails Surgical Equipment Sector Leaders
    May 19, 2026, 5:33 AM EDT. LeMaitre (NASDAQ:LMAT) reported Q1 revenue of $66.55 million, up 11.2% year-on-year but missed the mark relative to analyst estimates and offered weaker full-year guidance than peers. Despite beating earnings per share (EPS) estimates for the upcoming quarter, LMAT's stock fell 10%, trading at $100.83. In contrast, sector leader Intuitive Surgical (NASDAQ:ISRG) delivered a 23% revenue increase to $2.77 billion, surpassing expectations by 5.8%, driven by its robotic-assisted surgical systems business. The surgical equipment and consumables sector as a whole beat revenue estimates by 2.7% for Q1, with stocks rising an average of 6.4%. Industry growth is underpinned by aging populations and expanding use of AI and robotics, although challenges remain around R&D costs, regulatory compliance, pricing pressures, and potential supply chain issues.

Latest articles

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

19 May 2026
Alphabet shares rose in pre-market trading Tuesday after Google and Blackstone announced a U.S. AI cloud venture, with Blackstone committing $5 billion to add 500 megawatts of data-center capacity by 2027. Alphabet’s Class A shares closed Monday at $396.94 and were quoted at $401.09 before the market opened. The move coincides with the first day of Google I/O and follows strong Q1 earnings.
GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight

19 May 2026
GeoVax Labs shares surged nearly 80% to $2.21 Monday after announcing a $3 million private placement amid heightened interest in biodefense following a WHO emergency alert over Ebola in Africa. The company does not sell an approved Ebola vaccine; its lead candidate targets mpox and smallpox. GeoVax reported $1.3 million in cash at March 31 and a quarterly net loss of $5.3 million. The new funding is expected to close around May 19.
Evolution stock jumps on €2 billion move

Evolution stock jumps on €2 billion move

19 May 2026
Evolution AB shares surged 9% in Stockholm after the company announced a €2 billion share buyback, one of Sweden’s largest. The buyback starts immediately and may run until the 2027 annual meeting, capped at 10% of shares. The OMXS30 index rose just 0.75% in comparison. Evolution also secured a €300 million revolving credit facility from J.P. Morgan SE and Citibank Europe.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Winbond stock tumbles 8% at the open as Taiwan’s memory trade turns choppy again
Previous Story

Winbond stock tumbles 8% at the open as Taiwan’s memory trade turns choppy again

Telstra share price bucks ASX slide as miners sink; RBA call and Feb results loom
Next Story

Telstra share price bucks ASX slide as miners sink; RBA call and Feb results loom

Go toTop